Key facts
- Biotech One’s last known valuation is $4.9M (Dec 2025).
- It has raised $1.2M; the latest was Early Stage VC ($1.2M) in Dec 2025.
- Notable investors include Région Sud Investissement, CAAP Creation.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Biotech One
- ·The full record, as it builds
Funding rounds
No funding rounds for Biotech One are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biotech One
Developer of supercritical CO₂-based processing designed for industrial and healthcare applications. The company designs clean, solvent-free extraction, particle generation, encapsulation, and sterilization processes, enabling industrial and healthcare-oriented customers seeking to improve process sustainability, limit unwanted byproducts, and reduce processing time and operating costs.
- Sector
- Materials and Resources
- HQ
- Marseille, France
- Founded
- 2022
- Employees
- 5
- Website
- biotech-one.com/
- Ownership
- Privately Held (backing)
Biotech One doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biotech One shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biotech One in its N-PORT filings yet. We sweep new filings monthly.